This Regulated Markets Pharma Stock Rises 104% in 1 Year: What Is Driving the Re-Rating?

This regulated markets pharma stock has delivered a price return of approximately 104% in one year, turning Rs 1 lakh into roughly Rs 2.04 lakh. The figure is a close to close calculation from Rs 686.50 on 16 September 2025 to about Rs 1,403 on 16 September 2026, with no split or bonus in between. That made it one of the strongest performers on a screen of NSE small-cap stocks ranked by 1-year return, dated 16 September 2026.

The company is Senores Pharmaceuticals Ltd (NSE: SENORES), an Ahmedabad based drugmaker that listed in December 2024 and sells mainly into the United States and Canada. Unlike many recent listings that faded after a few months, this regulated markets pharma stock kept compounding on quarterly numbers. It buys or files approved product dossiers, plugs them into owned manufacturing, and sells where regulatory barriers keep competition limited.

Click Here – Get Free Investment Predictions

How Much Has This Regulated Markets Pharma Stock Actually Gained in 1 Year?

The verified 1-year price return is approximately 104%. The Senores Pharmaceuticals share price closed at Rs 686.50 on 16 September 2025 and traded around Rs 1,403 on 16 September 2026, against a previous close of Rs 1,416.10. In that window the regulated markets pharma stock hit a 52-week high of Rs 1,599 on 24 August 2026 and a low of Rs 662.45 on 29 September 2025.

The rise was not linear. Most of the move came between March and August 2026, and the last month has been profit booking. Here is how the regulated markets pharma stock has performed across time frames:

Period	From	Price Return
1 Month	Rs 1,477.70 (14 Aug 2026)	Approximately -5%
3 Months	Rs 1,257.20 (16 Jun 2026)	Approximately 12%
6 Months	Rs 744.30 (16 Mar 2026)	Approximately 89%
1 Year	Rs 686.50 (16 Sep 2025)	Approximately 104%
Since Listing	Rs 557.05 (30 Dec 2024)	Approximately 152%
Versus IPO Price	Rs 391 (issue)	Approximately 259%

Returns are simple price changes and are not annualised. The company listed on 30 December 2024, so a full one-year window exists while a three-year or five-year record does not. The stock debuted at a premium of about 52% over the Rs 391 issue price.

The 1-month reading is negative. This regulated markets pharma stock now trades around 12% below its 52-week high, a reminder that a 104% annual gain can carry sharp drawdowns inside it.

Why Did This Regulated Markets Pharma Stock Rise 104%?

Four things drove the move: rapid growth in the US and Canada business, an approved product portfolio that nearly doubled, bolt-on acquisitions, and guidance that management kept meeting. Each changed the earnings base of the regulated markets pharma stock, not just sentiment around it.

1. The US and Canada Business Is Doing the Heavy Lifting

In the June 2026 quarter, regulated markets revenue was approximately Rs 127.8 crore, up about 42% year on year and roughly 71% of total revenue, at an EBITDA margin of around 40%. For FY26, that segment grew approximately 75% to about Rs 427 crore.

Emerging markets grew around 30% to approximately Rs 37.6 crore at a margin near 14%, while the branded generics business slipped about 2%. The profit engine of this regulated markets pharma stock is its North American portfolio, and that concentration works both ways.

2. The Approved Product Portfolio Nearly Doubled

Approved ANDAs rose from 30 in June 2025 to 58 in June 2026. Of these, 23 are commercialised and around 35 are still to be launched, which is the visible pipeline behind the regulated markets pharma stock. Commercialised contract manufacturing products moved up from 27 to 34.

3. Acquisitions Bought Growth Instead of Waiting for It

The company acquired 14 ANDAs from a large Indian drugmaker in March 2025, took rights to a dermatology molecule, and bought a majority stake in Apnar Pharma for approximately Rs 91 crore, adding five ANDAs and a USFDA approved facility. It also added Zoraya Pharmaceuticals for US distribution and set up the Amerisyn joint venture for federal and Veterans Affairs procurement.

4. Guidance That Management Kept Meeting

Senores Pharmaceuticals has met or beaten its own guidance in every quarter since listing. FY27 guidance is revenue growth of approximately 30% to 40% and profit growth of 50% to 60%, with capex of around Rs 130 crore for oral solid capacity and an injectable pilot plant. Roughly Rs 162 crore of the Rs 500 crore IPO proceeds has gone into inorganic growth. The stated ambition of Rs 2,500 crore to Rs 3,000 crore revenue in three to four years is what keeps a premium multiple on this regulated markets pharma stock.

Check the Univest Screener for Live Fundamentals of High-Return Stocks

Financials Behind the Regulated Markets Pharma Stock

FY26 total income was approximately Rs 664 crore against about Rs 418 crore in FY25, and net profit roughly doubled to approximately Rs 122 crore from Rs 58 crore. In the June 2026 quarter, revenue from operations rose around 36% year on year to about Rs 180.2 crore, EBITDA about 87% to Rs 54 crore and net profit about 56% to Rs 31 crore.

The quarterly trend for this regulated markets pharma stock, on a total income basis, looks like this:

Quarter	Total Income (Rs Cr)	EBITDA (Rs Cr)	Net Profit (Rs Cr)	Operating Margin
Jun 2025	146.78	37.52	21.18	28.80%
Sep 2025	167.17	54.92	30.12	35.81%
Dec 2025	178.34	57.79	33.58	33.81%
Mar 2026	192.86	65.16	36.67	37.19%
Jun 2026	183.02	56.57	30.45	31.39%

Total income and profit dipped sequentially in the June 2026 quarter and the operating margin fell from 37.19% to 31.39%. That flat quarter is part of why the regulated markets pharma stock has drifted lower this month.

Debt to equity has fallen from 1.28 in FY24 to 0.58 in FY25 and approximately 0.37 now, while book value per share is about Rs 202.72. Return on equity of approximately 12.36% is modest for the multiple this regulated markets pharma stock commands.

Who Owns This Regulated Markets Pharma Stock?

Promoters held 45.82% in June 2026, almost unchanged since listing. The clearest shift is foreign institutional holding, which nearly doubled from 3.64% in March 2026 to 6.62% in June 2026.

Shareholder	Jun 2025	Dec 2025	Mar 2026	Jun 2026
Promoters	45.78%	45.80%	45.82%	45.82%
FIIs	3.67%	3.35%	3.64%	6.62%
DIIs	9.51%	9.31%	9.61%	9.77%
Public and Others	41.04%	41.54%	40.93%	37.79%

Domestic institutions inched up from 9.51% to 9.77% and several diversified mutual fund schemes hold small positions. Public shareholding fell from 41.04% to 37.79%, so the free float of this regulated markets pharma stock is slowly moving into institutional hands.

Is This Regulated Markets Pharma Stock Expensive After a 104% Run?

On trailing numbers it is priced above its peer set. The regulated markets pharma stock trades at a PE of approximately 50 against an industry PE of about 38, with a price to book of around 7.01 and no dividend. Trailing earnings per share is Rs 28.41 and market capitalisation about Rs 6,543 crore.

The premium is defensible if profit grows 50% to 60% in FY27 as guided, since that would pull the forward multiple down sharply. Anyone buying this regulated markets pharma stock now is paying for the pipeline, not for profits already reported.

Key Risks in This Regulated Markets Pharma Stock

Liquidity and volatility: This is a small cap with a market capitalisation near Rs 6,543 crore and daily volumes that often sit near one to two lakh shares on NSE. The regulated markets pharma stock swung between Rs 662.45 and Rs 1,599 in twelve months, and a single block trade can move the price.

Geography concentration: Around 71% of revenue comes from the United States and Canada, so any change in US drug pricing policy, import tariffs or procurement rules hits this regulated markets pharma stock directly.

Regulatory inspections: A US facility of group company Havix received three Form 483 observations after a July 2025 inspection. The company called them procedural and the unit was later cleared, but repeat findings at any site would be serious for a business built on approved filings.

Working capital: Working capital days rose from approximately 114 in FY25 to about 187 in FY26 as acquired businesses were absorbed, so cash conversion needs a check every quarter.

Promoter pledge: A promoter group entity created a pledge on 4,00,000 equity shares and later released a pledge of the same size. The amounts are small against the equity base, but such disclosures matter in a regulated markets pharma stock of this size.

Integration and price erosion: Generic prices in the US fall over time and several acquisitions are still being integrated. A slower launch schedule for the 35 approved but unlaunched products would change the earnings maths for this regulated markets pharma stock.

Download the Univest iOS App or Univest Android App to track the Senores Pharmaceuticals share price live

Senores Pharmaceuticals Share: Analyst View

Formal analyst coverage on this regulated markets pharma stock is thin, which is normal less than two years after listing. The last widely reported consensus was a buy stance with a target of approximately Rs 985.50 in January 2026, when the Senores Pharmaceuticals share price was around Rs 821.

The Senores Pharmaceuticals share price has since moved well past that level, so the January target is stale rather than a live view. No updated verified brokerage target is available for the Senores Pharmaceuticals share, and at least one research house carries a not rated note on the company.

Senores Pharmaceuticals Share Price Target

With no fresh verified Senores Pharmaceuticals share price target available, price levels matter more than estimates. The 52-week high of Rs 1,599 is the immediate resistance for the Senores Pharmaceuticals share price, and the Rs 1,250 to Rs 1,300 band, where the stock consolidated in June 2026, is the nearest support.

Any Senores Pharmaceuticals share price target from here rests on three assumptions: how fast the 35 unlaunched ANDAs reach the market, whether regulated markets margins hold near 40%, and whether FY27 profit growth lands in the guided 50% to 60% band. A brokerage target is an estimate, not a promise, and this regulated markets pharma stock already prices in plenty of optimism.

Other Stocks to Track From the Same Return Screen

Beyond this regulated markets pharma stock, a screen of NSE small-cap stocks ranked by 1-year return also includes related names such as Novartis India with a 1-year return of 126.70%, Morepen Labs at 99.55% and Man Industries at 112.76%.

Among the names covered from that screen, MTAR Technologies returned 396.53% over one year. Readers can compare this regulated markets pharma stock with the Nifty 50 benchmark and track each of these names on Univest before making any decision.

Conclusion

The 104% one-year gain in this regulated markets pharma stock rests on real numbers. Approved ANDAs went from 30 to 58, FY26 profit roughly doubled to about Rs 122 crore, and the US and Canada business grew approximately 75%.

The other side is a PE near 50, a flat June quarter, working capital days at 187, and a small cap price that can move 10% in a week. Existing holders of the Senores Pharmaceuticals share can track quarterly launches and cash conversion, while new investors may prefer staggered entries with a stop loss rather than chasing this regulated markets pharma stock after a 104% year. Consulting a SEBI registered advisor is sensible.

Frequently Asked Questions

Which regulated markets pharma stock rose 104% in 1 year?

Ans. Senores Pharmaceuticals (NSE: SENORES) is the regulated markets pharma stock that gained approximately 104% between 16 September 2025 and 16 September 2026, from a close of Rs 686.50 to about Rs 1,403. There was no stock split or bonus issue in that window.

Why did the Senores Pharmaceuticals share price rise so much?

Ans. The US and Canada business grew around 75% in FY26 to about Rs 427 crore and the approved ANDA count rose from 30 to 58. FY26 net profit roughly doubled to approximately Rs 122 crore, which re-rated the regulated markets pharma stock.

What were the latest quarterly results of Senores Pharmaceuticals?

Ans. For the June 2026 quarter, this regulated markets pharma stock reported revenue from operations of approximately Rs 180.2 crore, up about 36% year on year, and net profit of around Rs 31 crore, up roughly 56%. EBITDA rose about 87% to Rs 54 crore, though total income was slightly below the March 2026 quarter.

Is this regulated markets pharma stock expensive right now?

Ans. It trades at a PE of approximately 50 against an industry PE of about 38, with a price to book near 7.01 and return on equity of approximately 12.36%. The premium is justified only if the guided FY27 profit growth of 50% to 60% lands.

What is the 52-week high and low of Senores Pharmaceuticals?

Ans. The 52-week high of this regulated markets pharma stock is Rs 1,599, made on 24 August 2026, and the 52-week low is Rs 662.45 from 29 September 2025. The Senores Pharmaceuticals share price was around Rs 1,403 on 16 September 2026, about 12% below that high.

Have institutions been buying this regulated markets pharma stock?

Ans. Foreign institutional holding rose from 3.64% in March 2026 to 6.62% in June 2026 and domestic institutional holding moved up to 9.77%. Promoter holding was steady at 45.82%, while public shareholding fell to 37.79%.

What is the Senores Pharmaceuticals share price target?

Ans. No updated verified brokerage Senores Pharmaceuticals share price target is available at present. The last widely reported consensus target was approximately Rs 985.50 in January 2026, a level the share has already crossed, so the 52-week high of Rs 1,599 and support near Rs 1,250 are more useful reference points.

What are the main risks in this regulated markets pharma stock?

Ans. For this regulated markets pharma stock the main risks are small-cap liquidity and volatility, roughly 71% revenue concentration in the US and Canada, generic price erosion, and working capital days that rose from about 114 in FY25 to around 187 in FY26. A US facility of a group company also received three Form 483 observations in July 2025, later addressed.